Back to results
US 2025/0146017 A1Published application
Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
AssigneesCity of Hope, Imugene Limited
InventorsSaul J. Priceman, Anthony K. Park, Yuman Fong, Monil Shah
Life of this patent
Estimating the term…
Abstract
Described herein, inter alia, are oncolytic viruses expressing a truncated human CD19 (CD19t) and methods for treating a patient suffering from a solid tumor by administering an oncolytic virus expressing truncated human CD19 (OV19t), and optionally a T cell engager targeted to CD19.
Claims2
A method of treating a subject having a solid tumor comprising:
- administering to the subject an effective amount of an oncolytic virus expressing a truncated CD19 (OV19t), the nucleotide sequence of OV19t comprising:
- (a) an oncolytic virus nucleotide sequence;
- and
- (b) a nucleotide sequence encoding a truncated human CD19;
- and
- administering to the subject an effective amount of a bispecific T cell engager (TCE) that binds to CD19.
3 more elements
-64. (canceled)
Dependencies are inferred from the claim text.